Residual Weakness and Recurarization After Sugammadex Administration in Pediatric Patients: A Case Series

Area of Science:

• Anesthesiology
• Pediatric Critical Care
• Pharmacology

Background:

• Sugammadex is a reversal agent for neuromuscular blocking agents like rocuronium.
• While generally considered safe in pediatric patients, post-administration adverse events have been reported.

Observation:

• Four pediatric cases of residual or recurrent neuromuscular weakness after sugammadex reversal are presented.
• Two infants experienced postoperative ventilatory distress potentially due to recurarization.
• One patient required rescue with neostigmine, and another had prolonged intubation despite normal train-of-four results.

Findings:

• Sugammadex administration in pediatric patients may be associated with residual weakness or recurarization.
• Clinical signs of neuromuscular blockade can persist or return despite sugammadex reversal.
• Train-of-four monitoring may not fully predict adequate reversal in all pediatric cases.

Implications:

• Clinicians should maintain a high index of suspicion for residual neuromuscular weakness in pediatric patients post-sugammadex.
• Further investigation into sugammadex efficacy and safety in pediatric populations is warranted.
• Alternative or adjunct reversal strategies may be necessary in certain pediatric cases.